1. Home
  2. PWM vs MRNS Comparison

PWM vs MRNS Comparison

Compare PWM & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWM
  • MRNS
  • Stock Information
  • Founded
  • PWM 2018
  • MRNS 2003
  • Country
  • PWM Hong Kong
  • MRNS United States
  • Employees
  • PWM N/A
  • MRNS N/A
  • Industry
  • PWM
  • MRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PWM
  • MRNS Health Care
  • Exchange
  • PWM Nasdaq
  • MRNS Nasdaq
  • Market Cap
  • PWM 34.6M
  • MRNS 29.9M
  • IPO Year
  • PWM 2023
  • MRNS 2014
  • Fundamental
  • Price
  • PWM $1.45
  • MRNS $0.55
  • Analyst Decision
  • PWM
  • MRNS Buy
  • Analyst Count
  • PWM 0
  • MRNS 12
  • Target Price
  • PWM N/A
  • MRNS $4.28
  • AVG Volume (30 Days)
  • PWM 939.3K
  • MRNS 1.4M
  • Earning Date
  • PWM 02-14-2025
  • MRNS 03-04-2025
  • Dividend Yield
  • PWM N/A
  • MRNS N/A
  • EPS Growth
  • PWM N/A
  • MRNS N/A
  • EPS
  • PWM N/A
  • MRNS N/A
  • Revenue
  • PWM $348,528.00
  • MRNS $31,466,000.00
  • Revenue This Year
  • PWM N/A
  • MRNS $14.97
  • Revenue Next Year
  • PWM N/A
  • MRNS $57.65
  • P/E Ratio
  • PWM N/A
  • MRNS N/A
  • Revenue Growth
  • PWM N/A
  • MRNS 1.63
  • 52 Week Low
  • PWM $0.67
  • MRNS $0.22
  • 52 Week High
  • PWM $2.70
  • MRNS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • PWM 51.87
  • MRNS 70.09
  • Support Level
  • PWM $1.02
  • MRNS $0.54
  • Resistance Level
  • PWM $2.70
  • MRNS $0.55
  • Average True Range (ATR)
  • PWM 0.36
  • MRNS 0.01
  • MACD
  • PWM -0.02
  • MRNS -0.01
  • Stochastic Oscillator
  • PWM 29.38
  • MRNS 93.00

About PWM Prestige Wealth Inc.

Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Share on Social Networks: